147 related articles for article (PubMed ID: 8242613)
1. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma.
Finke JH; Zea AH; Stanley J; Longo DL; Mizoguchi H; Tubbs RR; Wiltrout RH; O'Shea JJ; Kudoh S; Klein E
Cancer Res; 1993 Dec; 53(23):5613-6. PubMed ID: 8242613
[TBL] [Abstract][Full Text] [Related]
2. T-cell receptor zeta-chain expression on tumor-infiltrating lymphocytes from renal cell carcinoma.
Cardi G; Heaney JA; Schned AR; Phillips DM; Branda MT; Ernstoff MS
Cancer Res; 1997 Aug; 57(16):3517-9. PubMed ID: 9270022
[TBL] [Abstract][Full Text] [Related]
3. Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy.
Bukowski RM; Rayman P; Uzzo R; Bloom T; Sandstrom K; Peereboom D; Olencki T; Budd GT; McLain D; Elson P; Novick A; Finke JH
Clin Cancer Res; 1998 Oct; 4(10):2337-47. PubMed ID: 9796963
[TBL] [Abstract][Full Text] [Related]
4. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma.
Lai P; Rabinowich H; Crowley-Nowick PA; Bell MC; Mantovani G; Whiteside TL
Clin Cancer Res; 1996 Jan; 2(1):161-73. PubMed ID: 9816103
[TBL] [Abstract][Full Text] [Related]
5. Partial degradation of T-cell signal transduction molecules by contaminating granulocytes during protein extraction of splenic T cells from tumor-bearing mice.
Franco JL; Ghosh P; Wiltrout RH; Carter CR; Zea AH; Momozaki N; Ochoa AC; Longo DL; Sayers TJ; Komschlies KL
Cancer Res; 1995 Sep; 55(17):3840-6. PubMed ID: 7641202
[TBL] [Abstract][Full Text] [Related]
6. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma.
Nakagomi H; Petersson M; Magnusson I; Juhlin C; Matsuda M; Mellstedt H; Taupin JL; Vivier E; Anderson P; Kiessling R
Cancer Res; 1993 Dec; 53(23):5610-2. PubMed ID: 8242612
[TBL] [Abstract][Full Text] [Related]
7. Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: a mechanism of immune escape.
Rayman P; Uzzo RG; Kolenko V; Bloom T; Cathcart MK; Molto L; Novick AC; Bukowski RM; Hamilton T; Finke JH
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S81-7. PubMed ID: 10685665
[TBL] [Abstract][Full Text] [Related]
8. Loss of T-cell receptor-CD3zeta and T-cell function in tumor-infiltrating lymphocytes but not in tumor-associated lymphocytes in ovarian carcinoma.
Lockhart DC; Chan AK; Mak S; Joo HG; Daust HA; Carritte A; Douville CC; Goedegebuure PS; Eberlein TJ
Surgery; 2001 Jun; 129(6):749-56. PubMed ID: 11391375
[TBL] [Abstract][Full Text] [Related]
9. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy.
Rabinowich H; Banks M; Reichert TE; Logan TF; Kirkwood JM; Whiteside TL
Clin Cancer Res; 1996 Aug; 2(8):1263-74. PubMed ID: 9816296
[TBL] [Abstract][Full Text] [Related]
10. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors.
Alexander JP; Kudoh S; Melsop KA; Hamilton TA; Edinger MG; Tubbs RR; Sica D; Tuason L; Klein E; Bukowski RM
Cancer Res; 1993 Mar; 53(6):1380-7. PubMed ID: 8443817
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppression in renal cancer: differential expression of signal transduction molecules in tumor-infiltrating, near-tumor tissue, and peripheral blood lymphocytes.
Riccobon A; Gunelli R; Ridolfi R; De Paola F; Flamini E; Fiori M; Saltutti C; Petrini M; Fiammenghi L; Stefanelli M; Granato AM; Cuzzocrea DE; Amadori D
Cancer Invest; 2004; 22(6):871-7. PubMed ID: 15641485
[TBL] [Abstract][Full Text] [Related]
12. Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients.
Viey E; Lucas C; Romagne F; Escudier B; Chouaib S; Caignard A
J Immunother; 2008 Apr; 31(3):313-23. PubMed ID: 18317356
[TBL] [Abstract][Full Text] [Related]
13. [The expression of zeta-chain of the T cell receptor as prognostic marker for patients with head and neck cancer].
Müller D; Lang S; Roskrow M; Wollenberg B
Laryngorhinootologie; 2002 Jul; 81(7):516-20. PubMed ID: 12173063
[TBL] [Abstract][Full Text] [Related]
14. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma.
Reichert TE; Strauss L; Wagner EM; Gooding W; Whiteside TL
Clin Cancer Res; 2002 Oct; 8(10):3137-45. PubMed ID: 12374681
[TBL] [Abstract][Full Text] [Related]
15. Sequential development of structural and functional alterations in T cells from tumor-bearing mice.
Correa MR; Ochoa AC; Ghosh P; Mizoguchi H; Harvey L; Longo DL
J Immunol; 1997 Jun; 158(11):5292-6. PubMed ID: 9164948
[TBL] [Abstract][Full Text] [Related]
16. Human renal cell carcinoma antigen-specific CTLs: antigen-driven selection and long-term persistence in vivo.
Jantzer P; Schendel DJ
Cancer Res; 1998 Jul; 58(14):3078-86. PubMed ID: 9679974
[TBL] [Abstract][Full Text] [Related]
17. [Zeta chain level of T and NK cells in patients with renal-cell carcinoma and bladder cancer and its clinical significance].
Han Y; Li CL; Lu L; Zhou CX; Ma WB; Wang DM; Zhang SR
Zhonghua Zhong Liu Za Zhi; 2004 Mar; 26(3):158-60. PubMed ID: 15196436
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
[TBL] [Abstract][Full Text] [Related]
19. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines.
Mulders P; Tso CL; Gitlitz B; Kaboo R; Hinkel A; Frand S; Kiertscher S; Roth MD; deKernion J; Figlin R; Belldegrun A
Clin Cancer Res; 1999 Feb; 5(2):445-54. PubMed ID: 10037196
[TBL] [Abstract][Full Text] [Related]
20. Tumor cells regulate the lytic activity of tumor-specific cytotoxic t lymphocytes by modulating the inhibitory natural killer receptor function.
Gati A; Guerra N; Giron-Michel J; Azzarone B; Angevin E; Moretta A; Chouaib S; Caignard A
Cancer Res; 2001 Apr; 61(8):3240-4. PubMed ID: 11309272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]